Single Source: Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Clinical Trial Data Processing, Analysis, and Coordination Center
ID: 359699Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359699
Timeline
    Description

    The National Institutes of Health (NIH) is offering a cooperative agreement opportunity for the Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) Clinical Trial Data Processing, Analysis, and Coordination Center. This initiative aims to renew support for core program activities, including the management, direction, and coordination of data processing and analysis to bolster the AMP SCZ Clinical Trial Network. The program is crucial for advancing research on pharmacological interventions for psychosis and requires collaboration among experts in clinical research and bioinformatics. The estimated total funding for this opportunity is $12 million, with one award anticipated. Interested applicants can reach out to Dr. Suzanne Garcia at suzanne.garcia@nih.gov or call 202-345-1260 for further information. Key dates include an estimated synopsis post date of September 24, 2025, and a close date of October 24, 2025, with project activities expected to commence on July 1, 2026.

    Point(s) of Contact
    Suzanne Garcia, PhD National Institute of Mental Health (NIMH)
    (202) 345-1260
    suzanne.garcia@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    The Accelerating Medicines Partnership (AMP) in Common Metabolic Diseases (CMD) Knowledge Portal: Roadmap for Future Development (Cooperative Agreement, Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a cooperative agreement opportunity titled "The Accelerating Medicines Partnership (AMP) in Common Metabolic Diseases (CMD) Knowledge Portal: Roadmap for Future Development," aimed at enhancing the understanding of complex metabolic diseases, particularly Type 2 Diabetes (T2D). This initiative seeks to renew the AMP CMD UM1 program for an additional five years, focusing on the aggregation and collation of genetic data related to T2D and its complications, thereby facilitating research and therapeutic advancements in the field. The program is critical for leveraging human genetics to uncover disease mechanisms and potential biomarkers, with an estimated total funding of $3 million and the expectation of one award. Interested applicants, including small businesses and various organizations, should contact Dr. Norann Zaghloul at Norann.zaghloul@nih.gov or call 301-435-6677 for further details, with proposals due by March 1, 2026, and awards anticipated by December 1, 2026.
    Notice of Intent to Publish a Notice of Funding Opportunity for Coordination Center for the Alzheimer�s Disease Sequencing Project Consortium (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Coordination Center for the Alzheimer’s Disease Sequencing Project Consortium, aimed at advancing research in Alzheimer's disease genetics. This initiative, which follows the approval of the concept by the National Advisory Council on Aging, will invite applications under an open competition framework, expanding eligibility for potential applicants. The funding opportunity is critical for fostering collaborations and innovative projects in the field of health, with an estimated total program funding of $1.6 million and a maximum award ceiling of $1 million for the selected applicant. The NOFO is expected to be published in November 2024, with applications due by February 14, 2025, and awards anticipated to be made by September 1, 2025.
    National Alzheimer’s Coordinating Center (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is set to publish a Notice of Funding Opportunity (NOFO) for the establishment of a National Alzheimer's Coordinating Center (NACC) under a cooperative agreement. The NACC aims to serve as a national data resource for Alzheimer's disease and related dementias (AD/ADRD) research, facilitating data collection from Alzheimer’s Disease Research Centers (ADRCs) and enhancing communication within the ADRC program. This initiative is crucial for advancing research in the field of aging and dementia, providing a centralized hub for collaboration and data sharing. Interested small businesses are encouraged to prepare for the application process, with the estimated synopsis posting date on August 15, 2025, and the anticipated award date set for July 15, 2026. For further inquiries, potential applicants can contact Dr. Cerise Elliott at elliottce@nih.gov or by phone at 301-496-9350.
    Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Schizophrenia and Related Disorders During Mid- to Late-Life," aimed at advancing research on the emergence and trajectory of schizophrenia and related disorders in individuals aged 35 and older. This initiative seeks to identify biological, psychosocial, and environmental mechanisms affecting this population to develop effective prevention and treatment strategies, addressing a critical gap in mental health research. The funding utilizes the R01 grant mechanism, with applications accepted starting January 5, 2025, and a project period of up to five years. Eligible applicants include a wide range of institutions and organizations, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov. The application deadline is September 7, 2026.
    Establishing Pediatric CNS Pharmacodynamic Measures as Tools to Enable Psychiatric Indications in Adolescents
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a cooperative agreement opportunity titled "Establishing Pediatric CNS Pharmacodynamic Measures as Tools to Enable Psychiatric Indications in Adolescents." This initiative aims to advance research in determining optimal dosing strategies for new psychiatric medications in children and adolescents suffering from serious mental illnesses, focusing on the development of central nervous system (CNS) tools and models to assess medication effects on the brain. The opportunity is particularly relevant for researchers with expertise in pediatric psychiatry, neuroimaging, and clinical pharmacology, as it seeks to improve the safety and effectiveness of pediatric clinical trials through the establishment of pharmacodynamic measures. Interested applicants can reach out to Dr. Margaret C. Grabb at mgrabb@mail.nih.gov or by phone at 301-443-3563 for further information, with the estimated synopsis post date set for December 13, 2025, and the close date anticipated for February 13, 2026.
    Schizophrenia and related disorders during mid- to late-life (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Schizophrenia and Related Disorders During Mid- to Late-Life" (PAR-24-026), aimed at advancing research on the onset and progression of schizophrenia and related disorders in individuals aged 35 and older. This initiative seeks to promote high-risk exploratory and developmental projects that investigate neurobiological, psychosocial, and environmental factors contributing to these disorders, with a particular emphasis on addressing health disparities among minority and aging populations. The program offers a maximum funding amount of $275,000 over two years, with applications due by November 16, 2023, for the initial cycle. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)" aimed at advancing research on schizophrenia and related disorders in individuals aged 35 and older. This initiative seeks to explore the mechanisms, trajectories, and outcomes of these disorders, with a focus on identifying targets for prevention and treatment interventions, particularly emphasizing the inclusion of diverse research teams and individuals with lived experience. The funding is available through the R01 grant mechanism, with applications due by September 7, 2026, and interested applicants are encouraged to adhere strictly to the application guidelines and contribute data to the National Institute of Mental Health Data Archive. For further information, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-023.html.
    Addressing Methodological Challenges with Clinical Trials of Psychotomimetic Agents
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Addressing Methodological Challenges with Clinical Trials of Psychotomimetic Agents," aimed at soliciting research applications that tackle the methodological issues associated with clinical trials involving psychotomimetic agents (PMAs). The focus of this initiative is to enhance the understanding of the therapeutic effects of PMAs, such as psilocybin and MDMA, which have shown potential benefits for mental health disorders like depression and anxiety, thereby increasing confidence in clinical trial outcomes. The estimated total program funding is $5 million, with approximately five awards anticipated, and interested applicants are encouraged to engage with the FDA prior to submission to ensure compliance with regulatory requirements. For further inquiries, potential applicants can contact Jonathan Sabbagh, Ph.D., at jonathan.sabbagh@nih.gov or by phone at 301-793-3534. The synopsis is expected to be posted on September 3, 2025, with applications closing on November 3, 2025, and awards anticipated by July 1, 2026.
    Establishing a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics through Training and Preclinical Support
    National Institutes of Health
    The National Institutes of Health (NIH) is seeking to establish a Center for the Advancement of Substance Use Disorder (SUD) Pharmacotherapeutics through a Cooperative Agreement aimed at enhancing the development of new pharmacotherapeutics for SUD. The Center will focus on educating researchers in formal product development and providing technical and financial support for initial experiments, with an emphasis on creating a product development curriculum and fostering collaborations within the research community. This initiative is crucial for advancing drug addiction research and supporting the translation of innovative concepts into practical applications. The estimated total program funding is $3 million, with one award expected, and interested parties can contact Dr. Tam Nguyen at Tam.Nguyen@nih.gov or (301) 451-1203 for further information. The estimated synopsis post date is November 21, 2025, with applications expected to close on January 27, 2026, and the project anticipated to start on September 1, 2026.
    Adult-Adolescent Brain Cognitive Development (A-ABCD) Study Renewal-Data Analysis, Informatics and Resource Center, and Coordinating Center (U24)
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the renewal of the Adult-Adolescent Brain Cognitive Development (A-ABCD) Study, specifically for the Data Analysis, Informatics and Resource Center, and the Coordinating Center. This initiative aims to continue the longitudinal study of brain development and health outcomes in a cohort of nearly 12,000 participants, following them from childhood into emerging adulthood to assess the impact of various factors on their development. The study utilizes advanced technologies, including brain scans and wearable sensors, to explore how experiences during young adulthood influence health and behavioral outcomes. Interested applicants, particularly existing awardees under RFA-DA-20-004 and RFA-DA-20-003, should note that applications are not currently being solicited, but they can prepare for future submissions. For further inquiries, contact Bethany Deeds, PhD, at deedsb@nida.nih.gov or by phone at 301-402-1935. The estimated synopsis post date is February 6, 2026, with a projected award date of April 1, 2027.